These cancers tend to be more aggressive with poorer prognosis (higher grade/size, lymphovascular-invasion positive, triple negative, HER2 positive, node positive, and medullary/metaplastic/micro-papillary/pleomorphic sub-types). This evidence concerns the gene ERBB2 and cancer.